Advertisement

Wirkungen des Vorhofhormons auf Venentonus und Sympathikusaktivität

  • J. Holtz
  • T. Münzel
Conference paper

Zusammenfassung

Von vielen Wirkungen des Vorhofhormons, die potentiell für die Regulation von Blutdruck und Extrazellulärvolumen bedeutsam sein könnten, ist noch nicht bekannt, welche physiologische Rolle sie spielen. Als Orientierungshilfe kann ein Vergleich von Plasmakonzentrationen des Hormons dienen, die einerseits im „Steady state“ bei Infusionen des synthetischen Hormons erreicht werden und die andererseits bei Eingriffen in die Blutdruck- und Volumenregulation spontan auftreten. Nach diesem Kriterium muß eine Infusionsrate von 0,1 μ, g/kg/min α-ANP in Hunden als Obergrenze für eine pathophysiologische Relevanz angesehen werden. In diesem Dosisbereich konnte keine direkte Verminderung des Venentonus (gemessen als effektive vaskuläre Dehnbarkeit) in narkotisierten Hunden unter autonomer Blockade festgestellt werden. In wachen Hunden bewirkte α-ANP jedoch eine relative Hemmung der Noradrenalinfreisetzung und eine absolute Hemmung der Adrenalinfreisetzung, und zwar um 24 ± 2% (SEM) pro 10fache Erhöhung des Plasma-ANP. Da die Schwelle für diese Hemmung im Bereich endogener ANP-Plasmakonzentrationen hegt und da diese sich parallel mit der Kochsalzzufuhr ändern, erscheint es möglich, daß diese Hemmung der sympathoadrenalen Aktivität durch αANP an der Blutdruck- und Volumenregulation bei Änderungen der Kochsalzzufuhr beteiligt ist.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Anderson JV, Millar ND, O’Hare JP, Mackenzie JC, Corrall RJM, Bloom SR (1986) Atrial natriuretic peptide: physiological release associated with natriuresis during water immersion in man. Clin Sci 71:319–322.PubMedGoogle Scholar
  2. 2.
    Ballermann BJ, Brenner BM (1985) Biologically active atrial peptides. J Clin Invest 76:2041–2048.CrossRefGoogle Scholar
  3. 3.
    Baxter JH, Wilson IB, Harris RB (1986) Identification of an endogenous protease that processes atrial natriuretic peptide at its amino terminus. Peptides 7:407–411.PubMedCrossRefGoogle Scholar
  4. 4.
    Breuhaus BA, Saneii HH, Brandt MA, Chimoskey JE (1985) Atriopeptin II lowers cardiac output in conscious sheep. Am J Physiol 249:R776–R780.PubMedGoogle Scholar
  5. 5.
    Crozier IG, Nicholls MG, Ikram H, Espiner EA, Yandle TG, Jans S (1986) Atrial natriuretic peptide in humans; production and clearance by various tissues. Hypertension 8:II11–II15.PubMedGoogle Scholar
  6. 6.
    Debinski W, Kuchel O, Buu NT, Garcia R, Cantin M, Genest J (1986) Involvement of the adrenal glands in the action of the atrial natriuretic factor. Proc Soc Biol Med 181:318–324.Google Scholar
  7. 7.
    De Bold AJ, Borenstein HB, Veress AT, Sonnenberg H (1981) A rapid and potent response to intravenous injektion of atrial myocardial extracts in rats. Life Sci 28:89–94.PubMedCrossRefGoogle Scholar
  8. 8.
    Echt M, Düweling J, Gauer OH, Lange L (1974) Effective compliance of the total vascular bed and intrathoracic compartment derived from changes in central nervous pressure induced by volume changes in man. Circ Res 34:61–68.Google Scholar
  9. 9.
    Esler, M, Jackman G, Boblik A, Kelleher D, Jennings G, Leonhard P, Skews H, Korner P (1979) Determination of norepinephrine apparent release rate and clearance in humans. Life Sci 25:1461–1470.PubMedCrossRefGoogle Scholar
  10. 10.
    Flynn TG, De Bold ML, De Bold AJ (1983) The amino acid sequence of an atrial peptide with potent diuretic and natriuretic properties. Biochem Biophys Res Comm 117:859–865.PubMedCrossRefGoogle Scholar
  11. 11.
    Forssmann WG, Hock D, Kirchheim F, Metz J, Mutt V, Reinecke M (1984) Cardiac hormones: morphological and functional aspects. Clin Exp Hypert A 6:1873–1878.CrossRefGoogle Scholar
  12. 12.
    Garcia R, Thibault G, Gutkowska J, Horky K, Hamet P, Cantin M, Genest J (1985) Chronic infusion of low doses of atrial natriuretic factor (ANF Arg-101 — Tyr-126) reduces blood pressure in conscious SHR without apparent changes in sodium excretion. Proc Soc Exp Biol Med 179:396–401.PubMedGoogle Scholar
  13. 13.
    Gerbes AL, Arendt RM, Schnizer W, Silz S, Jüngst D, Zähringer J, Paumgartner G (1986) Regulation of atrial natriuretic factor release in man: effect of water immersion. Klin Wochenschr 64:666–667.PubMedCrossRefGoogle Scholar
  14. 14.
    Gibson TR, Wildey GM, Manaker S, Glembotski CC (1986) Autoradiographic localization and characterization of atrial natriuretic peptide binding sides in the central nervous system and adrenal gland. J Neurosci 6:2004–2011.PubMedGoogle Scholar
  15. 15.
    Goetz KL (1986) Atrial receptors, natriuretic peptides, and the kidney — current understanding. Mayo Clin Proc 61:600–603.PubMedGoogle Scholar
  16. 16.
    Goetz KL, Wang BC, Geer PG, Leadley RJ, Reinhardt HW (1986) Atrial stretch increases sodium excretion independently of release of atrial peptides. Am J Physiol 250:R946–R950.PubMedGoogle Scholar
  17. 17.
    Goetz KL, Wang BC, Geer PG, Sundet WD, Needleman P (1986) Effects of atriopeptin infusion versus effects of left atrial stretch in awake dogs. Am J Physiol 250:R221–R226.PubMedGoogle Scholar
  18. 18.
    Hodsman GP, Tsunoda K, Ogawa K, Johnston CI (1985) Effects of posture on circulating atrial natriuretic peptide. Lancet II:1427.CrossRefGoogle Scholar
  19. 19.
    Holtz J, Sommer O, Bassenge E (1987) Inhibition of sympatho-adrenal activity by atrial natriuretic factor in dogs. Hypertension (in press).Google Scholar
  20. 20.
    Holtz J, Stewart DJ, Eisner D, Bassenge E (1986) In vivo atrial peptide-venodilatation: Minimal potency to nitroglycerin in dogs. Life Sci 39:2177–2184.PubMedCrossRefGoogle Scholar
  21. 21.
    Kimura T, Abe K, Ota K, Omata K, Shoji M, Kudo K, Matsui K, Inoue M, Yasujima M, Yoshinaga K (1986) Effects of acute water load, hypertonic saline infusion, and furosemide administration on atrial natriuretic peptide and vasopressin release in humans. J Clin Endcrinol Metab 62:1003–1010.CrossRefGoogle Scholar
  22. 22.
    Kleinen HD, Volpe M, Odell G, Marion D, Atlas SA, Camargo MJ, Laragh JH, Maack T (1986) Cardiovascular effects of atrial natriuretic factor in anesthetized and conscious dogs. Hypertension 8:312–316.Google Scholar
  23. 23.
    Knapp MF, Hicks MN, Linden RJ, Mary DASG (1986) Evidence against ANP as a natriuretic hormone during atrial distension. J Endocr 109:R5–8.PubMedCrossRefGoogle Scholar
  24. 24.
    Koyama S, Nishida Y, Hosomi H, Abe Y (1986) Participation of baroreceptor reflexes in blood pressue and sympathetic nerve responses to a synthetic human atrial natriuretic peptide in anesthetized dogs. Eur J Pharmacol 127:43–48.PubMedCrossRefGoogle Scholar
  25. 25.
    Kramer HJ, Lichardus B (1986) Atrial natriuretic hormones — thirty years after the discovery of atrial volume receptors. Klin Wochenschr 64:719–731.PubMedCrossRefGoogle Scholar
  26. 26.
    Lang RE, Thölken H, Ganten D, Luft FC, Ruskoaho H, Unger T (1985) Atrial natriuretic factor — a circulating hormone stimulated by volume loading. Nature 314:264–266.PubMedCrossRefGoogle Scholar
  27. 27.
    Lappe RW, Smits JFM, Todt JA, Debets JJM, Wendt RL (1985) Failure of atriopeptin II to cause arterial vasodilation in the conscious rat. Circ Res 56:606–612.PubMedGoogle Scholar
  28. 28.
    Larose P, Meloche S, Du Souich P, De Léan A, Ong H (1985) Radioimmunoassay of atrial natriuretic factor: human plasma levels. Biochem Biophys Res Comm 130:553–558.PubMedCrossRefGoogle Scholar
  29. 29.
    Lawton W, Sinkey C, Fitz A, Mark A (1986) Renal vascular resistance and sympathetic nervous system activity are abnormally increased in salt loaded borderline hypertensives. Hypertension 8:836.Google Scholar
  30. 30.
    Ledsome JR, Wilson N, Courneya CA, Rankin AJ (1985) Release of atrial natriuretic peptide by atrial distension. Can J Physiol Pharmacol 63:739–742.PubMedCrossRefGoogle Scholar
  31. 31.
    McCarty R, Plunkett LM (1986) Forebrain binding sites for atrial natriuretic factor: alterations in spontaneously hypertensive (SHR) rats. Neurochem Int 9:117–183.CrossRefGoogle Scholar
  32. 32.
    McKenzie JC, Tanaka I, Misono KS, Inagami T (1985) Immunocytochemical localization of atrial natriuretic factor in the kidney, adrenal medulla, pituitary, and atrium of rat. J Histochem Cytochem 33:828–832.PubMedCrossRefGoogle Scholar
  33. 33.
    Murthy KK, Thibault G, Schiffrin EL, Garcia R, Chartier L, Gutkowska J, Genest J, Cantin M (1986) Disappearance of atrial natriuretic factor from circulation in the rat. Peptides 7:241–246.PubMedCrossRefGoogle Scholar
  34. 34.
    Nakamaru M, Inagami T (1986) Atrial natriuretic factor inhibits norepinephrine release evoked by sympathetic nerve stimulation in isolated perfused rat mesenteric arteries. Eur J Pharmacol 123:459–461.PubMedCrossRefGoogle Scholar
  35. 35.
    Naruse M, Obana K, Naruse K, Sugino N, Demura H, Shizume K, Inagami T (1985) Antisera to atrial natriuretic factor reduces urinary sodium excretion and increases plasma renin activity in rats. Biochem Biophys Res Comm 132:954–960.PubMedCrossRefGoogle Scholar
  36. 36.
    Needleman P, Greenwald JE (1986) Atriopeptin: a cardiac hormone intimately involved in fluid, electrolyte, and blood-pressure homeostasis. N Engl J Med 314:828–834.PubMedCrossRefGoogle Scholar
  37. 37.
    Quirion R, Dalpé M, Dam TV (1986) Characterization and distribution of receptors for the atrial natriuretic peptides in mammalian brain. Proc Natl Acad Sci 83:174–178.PubMedCrossRefGoogle Scholar
  38. 38.
    Richards AM, Ikram H, Yandle TG, Nicholls MG, Webster MWI, Espiner EA (1985) Renal, heamodynamic, and hormonal effects of human alpha atrial natriuretic peptide in healthy volunteers. Lancet 1:545–548.PubMedCrossRefGoogle Scholar
  39. 39.
    Richards AM, Nicholls MG, Espinder EA, Ikram H, Yandle TG, Joyce SL, Cullens MM (1985) Effects of alpha-human atrial natriuretic peptide in essential hypertension. Hypertension 7:812–817.PubMedGoogle Scholar
  40. 40.
    Saavedra JM, Correa FMA, Plunkett LM, Israel A, Kurihara M, Shigematsu K (1986) Binding ov angiotensin and atrial natriuretic peptide in brain of hypertensive rats. Nature 320:758–760.PubMedCrossRefGoogle Scholar
  41. 41.
    Sagnella GA, Markandu ND, Shore AC, MacGregor GA (1985) Effects of changes in dietary sodium intake and saline infusion on immunoreactive atrial natriuretic pepitde in human plasma. Lancet 11:1208–1211.CrossRefGoogle Scholar
  42. 42.
    Sagnella GA, Markandu ND, Shore AC, MacGregor GA (1986) Raised circulating levels of atrial natriuretic peptides in essential hypertension. Lancet 1:179–181.PubMedCrossRefGoogle Scholar
  43. 43.
    Saper CB, Standaert DG, Currie MG, Schwartz D, Geller DM, Needleman P (1985) Atriopeptin-immunoreactive neurons in the brain: presence in cardiovascular regulatory areas. Science 227:1047–1049.PubMedCrossRefGoogle Scholar
  44. 44.
    Sasaki A, Kida O, Kangawa K, Matsou H, Tanaka K (1985) Cardiosuppressive effect of α-human atrial natriuretic polypeptide (α-hANP) in spontaneously hypertensive rats. Eur J Pharmacol 115:321–324.PubMedCrossRefGoogle Scholar
  45. 45.
    Sasaki A, Kida O, Kangawa K, Matsou H, Tanaka K (1986) Involvement of sympathetic nerves in cardiosuppressive effects of α-human atrial natriuretic polypeptide (α-hANP) in anesthetized rats. Eur J Pharmacol 120:345–349.PubMedCrossRefGoogle Scholar
  46. 46.
    Schiebinger RJ, Linden J (1986) The influence of resting tension on immunoreactive atrial natriuretic peptide secretion by rat atria superfused in vitro. Circ Res 59:105–109.PubMedGoogle Scholar
  47. 47.
    Schiffrin EL, Gutkowska J, Kuchel O, Cantin M, Genest J (1985) Plasma concentration of atrial natriuretic factor in a patient with paroxysmal atrial tachycardia. N Engl J Med 312:1196.PubMedCrossRefGoogle Scholar
  48. 48.
    Seymour AA, Smith SG, Mazack EK, Blaine EH (1986) A comparison of synthetic rat and human atrial natriuretic factor in conscious dogs. Hypertension 8:211–216.PubMedGoogle Scholar
  49. 49.
    Shenker Y, Sider RS, Ostain EA, Grekin RJ (1985) Plasma levels of immunoreactive atrial natriuretic factor in healthy subjects and in patients with edema. J Clin Invest 76:1684–1687.PubMedCrossRefGoogle Scholar
  50. 50.
    Stewart DJ, Eisner D, Sommer O, Holtz J, Bassenge E (1986) Altered spectrum of nitroglycerin action in long term treatment: nitroglycerin specific venous tolerance with maintenance of arterial vasodepressor potency. Circulation 74:573–582.PubMedCrossRefGoogle Scholar
  51. 51.
    Sugawara A, Nakao K, Sakamoto M, Morii N, Yamada T, Itoh H, Shiono S, Imura H (1985) Plasma concentration of atrial natriuretic polypeptide in essential hypertension. Lancet 11:1426–1427.CrossRefGoogle Scholar
  52. 52.
    Uehlinger DE, Weidmann P, Gnädinger MP, Shaw S (1985) Effects of human atrial natriuretic peptide on the pressor action of noradrenaline and angiotensin II in normal subjects. J Hypert 3:S319–S321.Google Scholar
  53. 53.
    Waldman SA, Rapoport RM, Fiscus RR, Murad F (1985) Effects of atriopeptin on particulate guanylate cyclase from rat adrenal. Biochim Biophys Acta 845:298–303.PubMedCrossRefGoogle Scholar
  54. 54.
    Weidmann P, Hasler L, Gnädinger MP, Lang RE, Uehlinger DE, Shaw S, Rascher W, Reubi FC (1986) Blood levels and renal effects of atrial natriuretic peptide in normal man. J Clin Invest 77:734–742.PubMedCrossRefGoogle Scholar
  55. 55.
    Weidmann P, Hellmueller B, Uehlinger DE, Lang RE, Gnaedinger MP, Hasler L, Shaw S, Bachmann C (1986) Plasma levels and cardiovascular, endocrine, and excretory effects of atrial natriuretic peptide during different sodium intakes in man. J Clin Endocrinol Metab 62:1027–1036.PubMedCrossRefGoogle Scholar
  56. 56.
    Winquist RJ, Faison EP, Nutt RF (1984) Vasodilator profile of synthetic atrial natriuretic factor. Eur J Pharmacol 102:169–173.PubMedCrossRefGoogle Scholar
  57. 57.
    Yamaji T, Ishibashi M, Kakaoka M, Imataka K, Amano K, Fujii J (1985) Possible role for atrial natriuretic peptide in polyuria associated with paroxysmal atrial arrhythmias. Lancet 1:1211.PubMedCrossRefGoogle Scholar
  58. 58.
    Yandle TG, Espiner EA, Nicholls MG, Duff H (1986) Radioimmunoassay and characterization of atrial natriuretic peptide in human plasma. J Clin Endocrinol Metab 62:72–79.CrossRefGoogle Scholar
  59. 59.
    Yandle TG, Richards AM, Nicholls MG, Cuneo R, Espiner EA, Livesey JH (1986) Metabolic clearance rate and plasma half life of alpha-human atrial natriuretic peptide in man. Life Sci 38:1827–1833.PubMedCrossRefGoogle Scholar

Copyright information

© Dr. Dietrich Steinkopff Verlag, GmbH & Co. KG, Darmstadt 1988

Authors and Affiliations

  • J. Holtz
    • 1
    • 2
  • T. Münzel
    • 1
  1. 1.Institut für Angewandte Physiologie und BalneologieUniversität FreiburgDeutschland
  2. 2.Institut für Angewandte Physiologie und BalneologieUniversität FreiburgFreiburg i.Br.Deutschland

Personalised recommendations